U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223424) titled 'Patient Preference for Subcutaneous vs. Intravenous Immune Therapy' on Oct. 23.
Brief Summary: The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Renal Cell Carcinoma
Non Small Cell Lung Cancer
Melanoma
Colo-rectal Cancer (dMMR/MSI-H CRC)
Hepatocellular Carcinoma
Ulcerative Colitis
Esophageal Cancer
Squamous Cell Carcinoma
Gastric/GEJ
Cervical Cancer
Gastro-Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
Intervention:...